1/30/2007

Baxter International has renewed its focus on R&D by investing a record $614 million, according to its chairman. Already the world leader for blood disease treatments, Baxter has set its sights on new hemophilia therapies as well as stem cell therapies and Alzheimer's treatments.

Related Summaries